The Medicines Company have filed a patent suit against Teva Pharmaceutical Industries Ltd to attempt to protect their anti-clotting drug, Angiomax.
Angiomax (bivalirudin) is an anticoagulant that is used to lessen bleeding during heart procedures and may be injected during percutaneous coronary intervention, for example, to prevent clotting during angioplasty procedures.
Teva, the world’s largest generic drugmaker, could launch an Angiomax generic as early as this month. Angiomax’s patent will expire in March 2010. Medicines Co would have obtained a four year extension had they not missed the deadline to file for extended patent exclusivity by merely a day.
In addition to suing class=”hiddenSpellError” pre=”suing “>Teva Parenteral Medicines, Inc, the Medicines Company are also suing Pliva Hrvatska d.o.o. , APP Pharmaceuticals, LLC, and related entities in the United States District Court for the District of Delaware alleging patent infringement based on the Abbreviated New Drug Applications seeking US Food and Drug Administration approval to market and sell generic versions of The Medicines Company’s Angiomax product prior to the expiry of US Patent No. 7,582,727.
